Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8028869 | 1.00 | HTT (0.40) | HTTDGAT1KMT2ALMNACA12 | |
| SCHEMBL19407016 | 1.00 | HTT (0.40) | HTTDGAT1KMT2ALMNACA12 | |
| SCHEMBL8030378 | 1.00 | HTT (0.40) | HTTDGAT1KMT2ALMNACA12 | |
| SCHEMBL17243717 | 0.89 | HTT (0.34) | HTTDGAT1KMT2ALMNACA12 | |
| SCHEMBL6058611 | 0.89 | TSHR (0.50) | HTTDGAT1KMT2ALMNACA12 | |
| SCHEMBL18206870 | 0.89 | DGAT1 (0.44) | HTTDGAT1KMT2ALMNACA12 | |
| SCHEMBL11855010 | 0.86 | CA1 (0.39) | DGAT1KMT2ALMNACA12CA14 | |
| SCHEMBL4671957 | 0.86 | CA1 (0.39) | DGAT1KMT2ALMNACA12CA14 | |
| SCHEMBL16667110 | 0.86 | KMT2A (0.39) | HTTDGAT1KMT2ALMNACA12 | |
| SCHEMBL4671964 | 0.86 | CA1 (0.39) | DGAT1KMT2ALMNACA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115286510-A | L-tartaric acid di-tert-butyl ester crystal form and preparation method thereof | 山东药品食品职业学院 | 2022-11-04 | — | — | CN | claimed |
| WO-2000063152-A1 | ACETYLATED AND RELATED ANALOGUES OF CHICORIC ACID AS HIV INTEGRASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-10-26 | — | — | WO | claimed |
| CN-116917446-B | Hydroprocessing process using catalyst sequences with nickel, molybdenum and tungsten based catalysts | IFP Energies Nouvelles (FR) | 2026-05-26 | — | — | CN | disclosed |
| US-12629669-B2 | Method for rejuvenating a catalyst from a hydroprocessing and/or hydrocracking process | IFP Energies Nouvelles (FR) | 2026-05-19 | — | — | US | disclosed |
| EP-4558588-B1 | HYDROTREATMENT PROCESS USING A SEQUENCE OF CATALYSTS WITH A CATALYST BASED ON NICKEL AND TUNGSTEN ON A SILICA-ALUMINA SUPPORT | IFP ENERGIES NOW (FR) | 2026-05-13 | — | — | EP | disclosed |
| US-12590254-B2 | Method for hydrodesulfurisation of a petroleum fraction using a catalyst containing a graphitic material characterised by the H/C ratio thereof | IFP Energies Nouvelles (FR) | 2026-03-31 | — | — | US | disclosed |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCE INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12521702-B2 | Trimetallic catalyst made from nickel, molybdenum and tungsten and use thereof in a hydrotreatment and/or hydrocracking process | IFP Energies Nouvelles (FR) | 2026-01-13 | — | — | US | disclosed |
| US-12467003-B2 | Hydrotreating process using a sequence of catalyst with a catalyst based on nickel, molybdenum and tungsten | IFP Energies Nouvelles (FR) | 2025-11-11 | — | — | US | disclosed |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4558588-A1 | HYDROTREATMENT PROCESS USING A SEQUENCE OF CATALYSTS WITH A CATALYST BASED ON NICKEL AND TUNGSTEN ON A SILICA-ALUMINA SUPPORT | IFP Energies nouvelles (FR) | 2025-05-28 | — | — | EP | disclosed |
| US-20100152463-A1 | Methods for Preparing Fluoroalkyl Arylsulfinyl Compounds and Fluorinated Compounds Thereto | IM&T RESEARCH, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010022001-A1 | METHODS FOR PREPARING FLUOROALKYL ARYLSULFINYL COMPOUNDS AND FLUORINATED COMPOUNDS THERETO | IM&T RESEARCH, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20090082393-A1 | New addition salts of angiotensin-converting enzyme inhibitors with no donor acids, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2009-03-26 | — | — | US | disclosed |
| CN-101146809-A | Process for preparing quinoline compounds and products obtained therefrom | WYETH CORP (US) | 2008-03-19 | — | — | CN | disclosed |
| WO-2000063152-A1 | ACETYLATED AND RELATED ANALOGUES OF CHICORIC ACID AS HIV INTEGRASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-10-26 | — | — | WO | disclosed |
| EP-0094815-B1 | OLIGOPEPTIDE PRODRUGS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-01-11 | — | — | EP | disclosed |
| US-4479898-A | Oligopeptide prodrugs | SMITHKLINE BECKMAN CORPORATION (US) | 1984-10-30 | — | — | US | disclosed |
| US-4454065-A | INCREASE CELL MEMBRANE PERMEABILITY | SMITHKLINE BECKMAN CORPORATION (US) | 1984-06-12 | — | — | US | disclosed |
| EP-0094815-A2 | Oligopeptide prodrugs | SMITHKLINE BECKMAN CORPORATION (US) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152463-A1 | Methods for Preparing Fluoroalkyl Arylsulfinyl Compounds and Fluorinated Compounds Thereto | PFAS, AGPS, FDPS | HTT 2771/4885DGAT1 870/4885KMT2A 3317/4885 |
| US-12590254-B2 | Method for hydrodesulfurisation of a petroleum fraction using a catalyst containing a graphitic material characterised by the H/C ratio thereof | HMOX2, SCO2, HAO2 | HTT 1589/4885DGAT1 582/4885KMT2A 3494/4885 |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | HTT 3181/4885DGAT1 1401/4885KMT2A 3782/4885 |
| US-12629669-B2 | Method for rejuvenating a catalyst from a hydroprocessing and/or hydrocracking process | HOGA1, GK, PCK2 | HTT 177/4885DGAT1 1058/4885KMT2A 2571/4885 |
| US-20090082393-A1 | New addition salts of angiotensin-converting enzyme inhibitors with no donor acids, a process for their preparation and pharmaceutical compositions containing them | ACE, AGTR1, AGT | HTT 4634/4885DGAT1 2576/4885KMT2A 3071/4885 |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | CCR10, CCR1, CCR3 | HTT 4711/4885DGAT1 1321/4885KMT2A 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.